© 2020 MJH Life Sciences and OncLive. All rights reserved.
April 16, 2018
Lyndsay J. Willmott, MD, gynecologic oncologist, Arizona Oncology, discusses the mechanisms of resistance to PARP inhibitors that have been identified in ovarian cancer.
August 17, 2017
Lyndsay J. Willmott, MD, a gynecologic oncologist with Arizona Oncology, discusses the FDA approval of olaparib (Lynparza) in the maintenance setting for relapsed patients with platinum-sensitive ovarian cancer.